Clinical Trial · NCT06203613

Clinical Study of CLDN18.2 PET/CT for Noninvasive Diagnosis of Gastric and Pancreatic Cancer

Overview

In this study, we will investigate the diagnostic efficacy and safety of \[18F\]F-H3RESCA-3A12 and \[68Ga\]Ga-NOTA-3A12 in metastatic gastric and pancreatic cancers, and evaluate the sensitivity and specificity of the use of \[18F\]F-H3RESCA-3A12 and \[68Ga\]Ga-NOTA-3A12 for diagnosing metastatic gastric and pancreatic cancers . This study will provide a new method for the noninvasive target-specific diagnosis of gastric and pancreatic cancer, and provide intuitive and clear imaging basis for clinical diagnosis, differential diagnosis and treatment.

Sponsor

Huashan Hospital

Phase

N/A

Contacts

Yihui Guan, MD (CONTACT)

guanyihui@hotmail.com

13764308300

Fang Xie, PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT06203613

Drug / Compound

3A12

Isotope(s):

Target(s):

Claudin 18.2

Ligand Class: Small Proteins and Antibody Fragments

Chelator: H3RESCA

3A12

Isotope(s):

Target(s):

Claudin 18.2

Ligand Class: Small Proteins and Antibody Fragments

Chelator: NOTA

Eligibility

Inclusion

Inclusion criteria not yet provided.

Exclusion

\- (1) Severe hepatic or renal insufficiency; (2) Targeted therapy before radiotherapy or PET/CT scan. (3)Renal function: serum creatinine less than or equal to the upper limit of the normal range;Liver function: bilirubin, AST(SGOT)/ALT(SGPT) less than or equal to the upper limit of the normal range.(4) History of serious surgery in the last month. (5) Those who have participated in other clinical trials during the same period.